NeuroPace Q3 revenue drops 19% to $10.3M; net loss widens to $8.1M

NeuroPace Inc

2021-Q3 EPS reported -$1.81 revenue$34,186,000

Q3 total revenue $10.3M down 19% YoY; initial implant revenue $7.8M down 15%.
Net loss $8.1M vs $4.1M loss in prior year; gross margin 72.6% vs 75.0%.
Updated FY2021 guidance: total revenue $44-44.5M (7-8% growth), initial implant $33-33.5M.
Received IDE approval for clinical study to expand indication to primary generalized epilepsy.
Added Lisa Andrade to Board; submitted PMA supplement for longer battery life claim (nearly 11 yrs).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.